Page 106 - Demo

Chapter 410465. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013.66. Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2017. 67. Tate RL, Perdices M, Rosenkoetter U, Wakim D, Godbee K, Togher L, et al. Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: The 15-item Risk of Bias in N-of-1 Trials (RoBiNT) Scale. Neuropsychol Rehabil. 2013.68. Hoyer D, Zorrilla EP, Cottone P, Parylak S, Morelli M, Simola N, et al. Clinical Global Impression Scales. In: Encyclopedia of Psychopharmacology. 2010. 69. Guy W. ECDEU Assessment manual for Psuchopharmacology Revised: Clinical Global Impression. Nimh. 1976;1. 70. Shapiro EG, Nestrasil I, Ahmed A, Wey A, Rudser KR, Delaney KA, et al. Quantifying behaviors of children with Sanfilippo syndrome: The Sanfilippo Behavior Rating Scale. Mol Genet Metab. 2015;114(4). 71. Sappok T, Diefenbacher A, Gaul I, Bölte S. Validity of the social communication questionnaire in adults with intellectual disabilities and suspected autism spectrum disorder. Am J Intellect Dev Disabil. 2015;120(3). 72. Brooks WT, Benson BA. The validity of the social communication questionnaire in adults with intellectual disability. Res Autism Spectr Disord. 2013;7(2). 73. Chandler S, Charman T, Baird G, Simonoff E, Loucas T, Meldrum D, et al. Validation of the Social Communication Questionnaire in a population cohort of children with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(10). 74. Berument SK, Rutter M, Lord C, Pickles A, Bailey A. Autism screening questionnaire: Diagnostic validity. Br J Psychiatry. 1999;175(NOV.). 75. Dunn W. Sensory profile: User’s manual. San Antonio, TX: Psychological Corporation; 1999. 76. Williams ZJ, Failla MD, Gotham KO, Woynaroski TG, Cascio C. Psychometric Evaluation of the Short Sensory Profile in Youth with Autism Spectrum Disorder. J Autism Dev Disord. 2018;48(12). 77. Gaasterland CMW, Jansen-Van Der Weide MC, Weinreich SS, Van Der Lee JH. A systematic review to investigate the measurement properties of goal attainment scaling, towards use in drug trials. BMC Med Res Methodol. 2016.78. Fisher RS. The New Classification of Seizures by the International League Against Epilepsy 2017. Vol. 17, Current Neurology and Neuroscience Reports. 2017. 79. Wilkinson M, Dumontier M, Aalbersberg I. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data 3 (2016). Sci data. 2016;3. 80. Araujo A, Julious S, Senn S. Understanding variation in sets of N-of-1 trials. PLoS One. 2016.81. Neurophysiological Biomarker Toolbox [Internet]. [cited 2023 Jul 25]. Available from: http://www.nbtwiki.net/82. The MathWorks Inc. Natick, MA, R2022a.83. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017;377(1). 84. Cummings J, Montes A, Kamboj S, Cacho JF. The role of basket trials in drug development for neurodegenerative disorders. Vol. 14, Alzheimer’s Research and Therapy. 2022. Annelieke Muller sHL.indd 104 14-11-2023 09:07